The FIELD study investigators* SummaryBackground： Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease， partly owing to dyslipidaemia， which can be amenable to fibr.....
Björn Dahlöf， Peter S Sever， Neil R Poulter， Hans Wedel， D Gareth Beevers， Mark Caulfield， Rory Collins， Sverre E Kjeldsen， Arni Kristinsson，Gordon T McInnes， Jesper Mehlsen， Markku Nieminen， Eoin O´Brien.....
Lancet. 2004 Aug; 364(9435):685-696. Colhoun HM， Betteridge DJ， Durrington PN， et al; CARDS investigators. INTERPRETATION: Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular .....
JAMA. 2005;293:437-446. The CREATE-ECLA Trial Group Investigators Context： Glucose-insulin-potassium (GIK) infusion is a widely applicable， low-cost therapy that has been postulated to improve mortality in patients wit.....
JAMA. 2005;293:427-435. The CREATE Trial Group Investigators Context： Although reperfusion therapy， aspirin， -blockers， and angiotensin-converting enzyme inhibitors reduce mortality when used early in patients with a.....
Diabetologia. 1999 Nov;42(11):1293-301. Jonsson B， Cook JR， Pedersen TR. Stockholm School of Economics， Stockholm， Sweden.AIMS/HYPOTHESIS: The purpose of this study is to investigate the cost-effectiveness of simvast.....
Circulation. 1992 Aug;86(2):431-8. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators......
关注公众号
安卓客户端
